Does the media favor DCTH or INSP?

In the previous week, Inspire Medical Systems had 5 more articles in the media than Delcath Systems. MarketBeat recorded 9 mentions for Inspire Medical Systems and 4 mentions for Delcath Systems. Inspire Medical Systems' average media sentiment score of 1.24 beat Delcath Systems' score of -1.04 indicating that Inspire Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Inspire Medical Systems 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DCTH or LMAT?

In the previous week, Delcath Systems had 1 more articles in the media than LeMaitre Vascular. MarketBeat recorded 4 mentions for Delcath Systems and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.00 beat Delcath Systems' score of -1.04 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative LeMaitre Vascular 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ESTA or DCTH?

In the previous week, Establishment Labs had 3 more articles in the media than Delcath Systems. MarketBeat recorded 7 mentions for Establishment Labs and 4 mentions for Delcath Systems. Establishment Labs' average media sentiment score of 0.87 beat Delcath Systems' score of -1.04 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Is NVCR or DCTH more profitable?

Delcath Systems has a net margin of 0.56% compared to NovoCure's net margin of -21.25%. Delcath Systems' return on equity of 0.46% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Delcath Systems 0.56% 0.46% 0.42%

Does the media favor NVCR or DCTH?

In the previous week, Delcath Systems had 1 more articles in the media than NovoCure. MarketBeat recorded 4 mentions for Delcath Systems and 3 mentions for NovoCure. NovoCure's average media sentiment score of 0.86 beat Delcath Systems' score of -1.04 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer KMTS or DCTH?

In the previous week, Delcath Systems had 2 more articles in the media than Kestra Medical Technologies. MarketBeat recorded 4 mentions for Delcath Systems and 2 mentions for Kestra Medical Technologies. Kestra Medical Technologies' average media sentiment score of 0.54 beat Delcath Systems' score of -1.04 indicating that Kestra Medical Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Delcath Systems (DCTH) Competitors

$15.36 +0.32 (+2.13%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$15.06 -0.30 (-1.92%)

As of 10/9/2026 07:30 PM Eastern

Compare

DCTH vs. INSP, LMAT, ESTA, NVCR, and KMTS

Should you buy Delcath Systems stock or one of its competitors? Delcath Systems's main competitors and comparable companies include Inspire Medical Systems (INSP), LeMaitre Vascular (LMAT), Establishment Labs (ESTA), NovoCure (NVCR), and Kestra Medical Technologies (KMTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Delcath Systems compare to Inspire Medical Systems?

Delcath Systems (NASDAQ:DCTH) and Inspire Medical Systems (NYSE:INSP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Delcath Systems has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Inspire Medical Systems has a net margin of 15.03% compared to Delcath Systems' net margin of 0.56%. Inspire Medical Systems' return on equity of 8.64% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
Inspire Medical Systems	15.03%	8.64%	7.45%

Inspire Medical Systems has higher revenue and earnings than Delcath Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	6.25	$2.70M	$0.01	1,536.00
Inspire Medical Systems	$911.98M	2.18	$145.42M	$4.62	14.91

Delcath Systems presently has a consensus price target of $23.17, indicating a potential upside of 50.82%. Inspire Medical Systems has a consensus price target of $67.29, indicating a potential downside of 2.33%. Given Delcath Systems' stronger consensus rating and higher possible upside, equities analysts plainly believe Delcath Systems is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inspire Medical Systems	4 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.05

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are held by institutional investors. 19.4% of Delcath Systems shares are held by insiders. Comparatively, 2.2% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Inspire Medical Systems had 5 more articles in the media than Delcath Systems. MarketBeat recorded 9 mentions for Inspire Medical Systems and 4 mentions for Delcath Systems. Inspire Medical Systems' average media sentiment score of 1.24 beat Delcath Systems' score of -1.04 indicating that Inspire Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative
Inspire Medical Systems	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inspire Medical Systems beats Delcath Systems on 11 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to LeMaitre Vascular?

Delcath Systems (NASDAQ:DCTH) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Delcath Systems presently has a consensus target price of $23.17, indicating a potential upside of 50.82%. LeMaitre Vascular has a consensus target price of $110.60, indicating a potential upside of 37.07%. Given Delcath Systems' stronger consensus rating and higher probable upside, research analysts plainly believe Delcath Systems is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
LeMaitre Vascular	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Delcath Systems had 1 more articles in the media than LeMaitre Vascular. MarketBeat recorded 4 mentions for Delcath Systems and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.00 beat Delcath Systems' score of -1.04 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative
LeMaitre Vascular	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Delcath Systems has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

LeMaitre Vascular has a net margin of 25.02% compared to Delcath Systems' net margin of 0.56%. LeMaitre Vascular's return on equity of 15.63% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
LeMaitre Vascular	25.02%	15.63%	10.06%

LeMaitre Vascular has higher revenue and earnings than Delcath Systems. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	6.25	$2.70M	$0.01	1,536.00
LeMaitre Vascular	$262.43M	7.03	$57.73M	$2.85	28.31

Summary

LeMaitre Vascular beats Delcath Systems on 9 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Delcath Systems has a net margin of 0.56% compared to Establishment Labs' net margin of -15.82%. Delcath Systems' return on equity of 0.46% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
Delcath Systems	0.56%	0.46%	0.42%

Establishment Labs currently has a consensus price target of $100.25, indicating a potential upside of 62.56%. Delcath Systems has a consensus price target of $23.17, indicating a potential upside of 50.82%. Given Establishment Labs' stronger consensus rating and higher possible upside, analysts clearly believe Establishment Labs is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Delcath Systems	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Establishment Labs had 3 more articles in the media than Delcath Systems. MarketBeat recorded 7 mentions for Establishment Labs and 4 mentions for Delcath Systems. Establishment Labs' average media sentiment score of 0.87 beat Delcath Systems' score of -1.04 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Establishment Labs has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Delcath Systems has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	8.71	-$51.06M	-$1.31	N/A
Delcath Systems	$85.23M	6.25	$2.70M	$0.01	1,536.00

Summary

Establishment Labs beats Delcath Systems on 9 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Delcath Systems had 1 more articles in the media than NovoCure. MarketBeat recorded 4 mentions for Delcath Systems and 3 mentions for NovoCure. NovoCure's average media sentiment score of 0.86 beat Delcath Systems' score of -1.04 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

NovoCure has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Delcath Systems has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.59	-$136.23M	-$1.30	N/A
Delcath Systems	$85.23M	6.25	$2.70M	$0.01	1,536.00

NovoCure presently has a consensus price target of $21.20, indicating a potential upside of 45.40%. Delcath Systems has a consensus price target of $23.17, indicating a potential upside of 50.82%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Delcath Systems	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Delcath Systems has a net margin of 0.56% compared to NovoCure's net margin of -21.25%. Delcath Systems' return on equity of 0.46% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Delcath Systems	0.56%	0.46%	0.42%

84.6% of NovoCure shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Delcath Systems beats NovoCure on 12 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and Delcath Systems (NASDAQ:DCTH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

In the previous week, Delcath Systems had 2 more articles in the media than Kestra Medical Technologies. MarketBeat recorded 4 mentions for Delcath Systems and 2 mentions for Kestra Medical Technologies. Kestra Medical Technologies' average media sentiment score of 0.54 beat Delcath Systems' score of -1.04 indicating that Kestra Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kestra Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

61.1% of Delcath Systems shares are held by institutional investors. 5.3% of Kestra Medical Technologies shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Delcath Systems has lower revenue, but higher earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$106.73M	15.06	-$131.61M	-$2.67	N/A
Delcath Systems	$85.23M	6.25	$2.70M	$0.01	1,536.00

Delcath Systems has a net margin of 0.56% compared to Kestra Medical Technologies' net margin of -140.43%. Delcath Systems' return on equity of 0.46% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-140.43%	-63.83%	-44.76%
Delcath Systems	0.56%	0.46%	0.42%

Kestra Medical Technologies has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Kestra Medical Technologies currently has a consensus price target of $28.38, suggesting a potential upside of 5.17%. Delcath Systems has a consensus price target of $23.17, suggesting a potential upside of 50.82%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Delcath Systems	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Delcath Systems beats Kestra Medical Technologies on 13 of the 16 factors compared between the two stocks.

Get Delcath Systems News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCTH vs. The Competition

Export

Metric	Delcath Systems	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$521.87M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	1,537.54	25.57	274.15	26.16
Price / Sales	6.25	83.27	590.50	94.68
Price / Cash	287.71	31.87	76.38	53.09
Price / Book	4.88	5.93	11.21	6.34
Net Income	$2.70M	$146.18M	$3.50B	$381.90M
7 Day Performance	1.52%	-0.38%	-0.90%	-1.41%
1 Month Performance	-2.78%	-2.02%	-4.44%	-3.48%
1 Year Performance	46.85%	5.08%	6.96%	1.16%

Delcath Systems Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCTH Delcath Systems	2.9911 of 5 stars	$15.36 +2.1%	$23.17 +50.8%	+41.2%	$521.87M	$85.23M	1,537.54	156	News Coverage Negative News Analyst Downgrade
INSP Inspire Medical Systems	2.8083 of 5 stars	$70.79 +1.1%	$66.50 -6.1%	-14.1%	$2.05B	$911.98M	15.32	1,333	Positive News Analyst Upgrade
LMAT LeMaitre Vascular	4.0184 of 5 stars	$82.03 -0.4%	$110.60 +34.8%	-7.6%	$1.88B	$249.60M	28.85	655	Analyst Upgrade
ESTA Establishment Labs	3.3316 of 5 stars	$62.56 -4.2%	$100.25 +60.2%	+53.7%	$1.86B	$211.08M	N/A	1,004
NVCR NovoCure	3.0251 of 5 stars	$15.84 +0.1%	$21.20 +33.8%	+1.7%	$1.86B	$655.35M	N/A	1,605	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCTH) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Delcath Systems (DCTH) Competitors

DCTH vs. INSP, LMAT, ESTA, NVCR, and KMTS

How does Delcath Systems compare to Inspire Medical Systems?

Summary

How does Delcath Systems compare to LeMaitre Vascular?

Summary

How does Delcath Systems compare to Establishment Labs?

Summary

How does Delcath Systems compare to NovoCure?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Delcath Systems (DCTH) Competitors

DCTH vs. INSP, LMAT, ESTA, NVCR, and KMTS

How does Delcath Systems compare to Inspire Medical Systems?

Which has more risk and volatility, DCTH or INSP?

Is DCTH or INSP more profitable?

Which has better earnings and valuation, DCTH or INSP?

Do analysts recommend DCTH or INSP?

Do insiders and institutionals believe in DCTH or INSP?

Does the media favor DCTH or INSP?

Summary

How does Delcath Systems compare to LeMaitre Vascular?

Do analysts recommend DCTH or LMAT?

Does the media favor DCTH or LMAT?

Do institutionals & insiders believe in DCTH or LMAT?

Which has more risk and volatility, DCTH or LMAT?

Is DCTH or LMAT more profitable?

Which has better earnings & valuation, DCTH or LMAT?

Summary

How does Delcath Systems compare to Establishment Labs?

Is ESTA or DCTH more profitable?

Do analysts recommend ESTA or DCTH?

Does the media prefer ESTA or DCTH?

Do institutionals & insiders believe in ESTA or DCTH?

Which has more risk and volatility, ESTA or DCTH?

Which has higher earnings & valuation, ESTA or DCTH?

Summary

How does Delcath Systems compare to NovoCure?

Does the media favor NVCR or DCTH?

Which has more volatility and risk, NVCR or DCTH?

Which has higher earnings and valuation, NVCR or DCTH?

Do analysts recommend NVCR or DCTH?

Is NVCR or DCTH more profitable?

Do insiders and institutionals have more ownership in NVCR or DCTH?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Does the media prefer KMTS or DCTH?

Do insiders and institutionals have more ownership in KMTS or DCTH?

Which has better earnings & valuation, KMTS or DCTH?

Is KMTS or DCTH more profitable?

Which has more risk and volatility, KMTS or DCTH?

Do analysts recommend KMTS or DCTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools